Minal Barve

7.0k total citations · 3 hit papers
179 papers, 2.9k citations indexed

About

Minal Barve is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Minal Barve has authored 179 papers receiving a total of 2.9k indexed citations (citations by other indexed papers that have themselves been cited), including 142 papers in Oncology, 54 papers in Pulmonary and Respiratory Medicine and 36 papers in Molecular Biology. Recurrent topics in Minal Barve's work include Cancer Immunotherapy and Biomarkers (37 papers), Lung Cancer Treatments and Mutations (30 papers) and Colorectal Cancer Treatments and Studies (30 papers). Minal Barve is often cited by papers focused on Cancer Immunotherapy and Biomarkers (37 papers), Lung Cancer Treatments and Mutations (30 papers) and Colorectal Cancer Treatments and Studies (30 papers). Minal Barve collaborates with scholars based in United States, Australia and China. Minal Barve's co-authors include Karen Velastegui, James G. Christensen, Alexander I. Spira, John Nemunaitis, Neil Senzer, Joshua K. Sabari, Rona Yaeger, Ticiana Leal, Hirak Der‐Torossian and Melissa L. Johnson and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Minal Barve

168 papers receiving 2.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C

2022 269 citations Rona Yaeger, Meredith Pelster et al. profile →
First-in-Human Phase I/IB Dose-Finding Study of Adagrasib (MRTX849) in Patients With Advanced KRAS^G12C Solid Tumors (KRYSTAL-1)

2022 206 citations Pasi A. Jänne, Joshua K. Sabari et al. Journal of Clinical Oncology profile →
Adagrasib in Advanced Solid Tumors Harboring aKRAS^G12CMutation

2023 139 citations Tanios Bekaii‐Saab, Rona Yaeger et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Minal Barve United States	25	1.8k	1.3k	659	654	444	179	2.9k
Ester Fonsatti Italy	28	1.5k 0.8×	1.7k 1.3×	704 1.1×	974 1.5×	440 1.0×	64	3.3k
Claudia Voena Italy	29	1.2k 0.7×	1.4k 1.1×	581 0.9×	735 1.1×	359 0.8×	57	3.2k
Katherine M. Bell‐McGuinn United States	21	2.7k 1.5×	1.9k 1.5×	450 0.7×	546 0.8×	727 1.6×	53	3.9k
Trisha M. Wise‐Draper United States	30	1.2k 0.7×	1.2k 1.0×	418 0.6×	378 0.6×	437 1.0×	140	2.5k
Wen‐Jen Hwu United States	27	2.5k 1.4×	1.1k 0.8×	780 1.2×	1.0k 1.6×	163 0.4×	92	3.2k
Michael H. Tomasson United States	32	1.3k 0.7×	1.6k 1.3×	230 0.3×	486 0.7×	460 1.0×	116	3.5k
Anusha Kalbasi United States	18	1.5k 0.8×	545 0.4×	695 1.1×	1.2k 1.8×	238 0.5×	62	2.6k
Ann Cleverly United States	25	1.5k 0.8×	1.3k 1.0×	333 0.5×	530 0.8×	428 1.0×	54	2.6k
Surajit Dhara United States	15	1.0k 0.6×	1.7k 1.4×	303 0.5×	426 0.7×	410 0.9×	19	2.6k
Maarten L. Janmaat Netherlands	17	1.3k 0.7×	1.0k 0.8×	525 0.8×	567 0.9×	156 0.4×	28	2.4k

Countries citing papers authored by Minal Barve

Since Specialization

Citations

This map shows the geographic impact of Minal Barve's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Minal Barve with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Minal Barve more than expected).

Fields of papers citing papers by Minal Barve

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Minal Barve. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Minal Barve. The network helps show where Minal Barve may publish in the future.

Co-authorship network of co-authors of Minal Barve

This figure shows the co-authorship network connecting the top 25 collaborators of Minal Barve. A scholar is included among the top collaborators of Minal Barve based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Minal Barve. Minal Barve is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Heymach, John V., Frans L. Opdam, Minal Barve, et al.. (2025). HER2-Selective Tyrosine Kinase Inhibitor, Zongertinib (BI 1810631), in Patients With Advanced/Metastatic Solid Tumors With HER2 Alterations: A Phase Ia Dose-Escalation Study. Journal of Clinical Oncology. 43(11). 1337–1347. 10 indexed citations

Yap, Timothy A., Minal Barve, E.P. Hamilton, et al.. (2025). 924MO First data disclosure of the first-in-class DNA polymerase theta inhibitor, ART6043, as monotherapy and in combination with olaparib, in patients with molecularly-selected advanced solid tumors. Annals of Oncology. 36. S566–S567. 1 indexed citations

Falchook, Gerald S., Amita Patnaik, Debra L. Richardson, et al.. (2024). A Relative Bioavailability, Bioequivalence, and Food Effect Study of Niraparib Tablets in Patients with Advanced Solid Tumors. Clinical Therapeutics. 46(3). 228–238. 1 indexed citations

Berz, David, John V. Heymach, Frans L. Opdam, et al.. (2024). Beamion LUNG-1, a Phase Ia/Ib trial of the HER2-specific tyrosine kinase inhibitor, zongertinib (BI 1810631), in patients with HER2-driven tumors: outcomes according to HER2 aberration type. American Journal of Clinical Pathology. 162(Supplement_1). S127–S127. 1 indexed citations

Vaishampayan, Ulka N., Randy F. Sweis, Deepak Kilari, et al.. (2024). Phase 1 study (DRAGON) of SRK-181 (linavonkibart), a latent TGFβ1 inhibitor, combined with pembrolizumab in patients with anti-PD1 resistant advanced solid tumors: Updated results of expansion part.. Journal of Clinical Oncology. 42(16_suppl). 2507–2507. 1 indexed citations

Barve, Minal, et al.. (2024). Phase 1 study of CTX-471, a novel CD137 agonist antibody, in patients with progressive disease following PD-1/PD-L1 inhibitors in metastatic or locally advanced malignancies.. Journal of Clinical Oncology. 42(16_suppl). 2535–2535. 1 indexed citations

Xie, Hao, Anthony B. El-Khoueiry, Angela Alistar, et al.. (2024). A first-in-human trial of selective CDK7 inhibitor Q901, in patients with advanced solid tumors: Interim results of a phase I study (QRNT-009).. Journal of Clinical Oncology. 42(16_suppl). 3078–3078. 2 indexed citations

Kim, Richard D., Hirva Mamdani, Minal Barve, et al.. (2024). A phase 2a study of NT-I7 (efineptakin alfa), a long-acting IL-7, and pembrolizumab to evaluate efficacy, including overall survival, in hard-to-treat gastrointestinal tumors.. Journal of Clinical Oncology. 42(16_suppl). 2621–2621. 1 indexed citations

Yaeger, Rona, Nataliya V. Uboha, Tanios Bekaii‐Saab, et al.. (2024). Efficacy and Safety of Adagrasib plus Cetuximab in Patients with KRAS G12C-Mutated Metastatic Colorectal Cancer. Cancer Discovery. 14(6). 982–993. 44 indexed citations

10.

Miller, Claire, Roberto Sommavilla, Cindy L. O’Bryant, et al.. (2024). Pharmacokinetic study of capivasertib and the CYP3A4 substrate midazolam in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology. 94(2). 223–235. 1 indexed citations

11.

Heymach, John V., Nuria Kotecki, Hans Prenen, et al.. (2023). 665P First-in-human, phase Ia/b, dose-escalation/expansion study of KRAS G12C inhibitor BI 1823911, as monotherapy and combined with anticancer therapies, in patients (pts) with advanced or metastatic solid tumours harbouring a KRAS G12C mutation. Annals of Oncology. 34. S468–S468. 10 indexed citations

12.

Bekaii‐Saab, Tanios, Rona Yaeger, Alexander I. Spira, et al.. (2023). Adagrasib in Advanced Solid Tumors Harboring aKRAS^G12CMutation. Journal of Clinical Oncology. 41(25). 4097–4106. 139 indexed citations breakdown →

13.

Zhang, Jun, Melissa L. Johnson, Minal Barve, et al.. (2023). Practical Guidance for the Management of Adverse Events in Patients with KRASG12C-Mutated Non-Small Cell Lung Cancer Receiving Adagrasib. The Oncologist. 28(4). 287–296. 10 indexed citations

14.

Patnaik, Amita, Minal Barve, Manali Bhave, et al.. (2023). Abstract P4-01-35: A Phase 1 Study of the Oral CDK7 Inhibitor XL102 as a Single Agent and in Combination Therapy in Patients With Advanced Solid Tumors (QUARTZ-101): Initial Results From the Dose-Escalation Stage. Cancer Research. 83(5_Supplement). P4–1. 1 indexed citations

15.

Damodaran, Senthil, Ciara C. O’Sullivan, Ahmed Elkhanany, et al.. (2023). Open-label, phase II, multicenter study of lasofoxifene plus abemaciclib for treating women with metastatic ER+/HER2− breast cancer and an ESR1 mutation after disease progression on prior therapies: ELAINE 2. Annals of Oncology. 34(12). 1131–1140. 25 indexed citations

16.

Tolcher, Anthony W., Xiaohua Wu, Jian Zhang, et al.. (2023). A phase 1, first-in-human, open-label, dose escalation and dose expansion study of TST005 in patients with locally advanced or metastatic solid tumors.. Journal of Clinical Oncology. 41(16_suppl). 2531–2531. 5 indexed citations

17.

Camidge, D. Ross, Daniel Morgensztern, Rebecca S. Heist, et al.. (2021). Phase I Study of 2- or 3-Week Dosing of Telisotuzumab Vedotin, an Antibody–Drug Conjugate Targeting c-Met, Monotherapy in Patients with Advanced Non–Small Cell Lung Carcinoma. Clinical Cancer Research. 27(21). 5781–5792. 60 indexed citations

18.

Hamilton, Erika, Minal Barve, Anthony W. Tolcher, et al.. (2020). 836P Safety and efficacy of XMT-1536 in ovarian cancer: A subgroup analysis from the phase I expansion study of XMT-1536, a NaPi2b antibody-drug conjugate. Annals of Oncology. 31. S627–S628. 11 indexed citations

19.

Piha‐Paul, Sarina A., Jasgit C. Sachdev, Minal Barve, et al.. (2019). First-in-Human Study of Mivebresib (ABBV-075), an Oral Pan-Inhibitor of Bromodomain and Extra Terminal Proteins, in Patients with Relapsed/Refractory Solid Tumors. Clinical Cancer Research. 25(21). 6309–6319. 116 indexed citations

20.

Ribas, Antoni, Theresa Medina, Shivaani Kummar, et al.. (2018). SD-101 in Combination with Pembrolizumab in Advanced Melanoma: Results of a Phase Ib, Multicenter Study. Cancer Discovery. 8(10). 1250–1257. 237 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact